FNY Managed Accounts’s AstraZeneca AZN Stock Holding History

FNY Managed Accounts’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-215	Closed	-$41.2K	–	182
2014 Q2	$41.2K	Buy	+215	New	+$15.5K	0.15%	50

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

EIP

Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

FNY Managed Accounts's AZN Position: Q2 2017 in Review

FNY Managed Accounts sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 174 shares — an estimated $10K sold.

FNY Managed Accounts first reported a position in AZN in Q1 2016 and held it in 2 quarters. The position peaked at $92.9K in Q1 2016. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

FNY Managed Accounts reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
FNY Managed Accounts sold 174 AstraZeneca shares in Q2 2017, an estimated $10K.
FNY Managed Accounts first reported a position in AstraZeneca in Q1 2016 and held it in 2 quarters.
FNY Managed Accounts's AstraZeneca position peaked at $92.9K in Q1 2016.
466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.